Evidence map›Paper›PMID 36494496›Full record

Trial reportEsophagus : official journal of the Japan Esophageal Society2023

The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.

Shu Aoyama, Masaaki Motoori, Makoto Yamasaki, Osamu Shiraishi, Hiroshi Miyata, Motohiro Hirao, Atsushi Takeno, Keijiro Sugimura, Tomoki Makino, Koji Tanaka and 7 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Esophagus : official journal of the Japan Esophageal Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Shu Aoyama *Department of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-Ku, Osaka, Japan.
Masaaki Motoori *Department of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-Ku, Osaka, Japan. mmotoori@gh.opho.jp.ORCID 0000-0002-8529-2844
Makoto YamasakiDepartment of Surgery, Kansai Medical University, Hirakata, Japan.
Osamu ShiraishiDepartment of Surgery, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Hiroshi MiyataDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Motohiro HiraoDepartment of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Atsushi TakenoDepartment of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Keijiro SugimuraDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Tomoki MakinoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Koji TanakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Takuya HamakawaDepartment of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Kotaro YamashitaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Yutaka KimuraDepartment of Surgery, Kindai University Nara Hospital, Ikoma, Japan.
Kazumasa FujitaniDepartment of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-Ku, Osaka, Japan.
Takushi YasudaDepartment of Surgery, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Masahiko YanoDepartment of Surgery, Suita Municipal Hospital, Suita, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
The University of Osaka · JPKindai University · JPOsaka National Hospital · JPOsaka Prefectural Medical Center · JPKansai Medical University · JPKansai Rosai Hospital · JPOsaka International Cancer Institute · JPSuita Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant therapy followed by surgery is the standard treatment for locally advanced esophageal cancers. During neoadjuvant therapy, tumor-induced esophageal stenosis or adverse events often cause weight loss. However, little is known about the effects of weight loss during neoadjuvant therapy on postoperative complications or prognosis. We investigated the association between weight loss during neoadjuvant chemotherapy, postoperative infectious complications, and prognosis.

methodsData from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used. Body weight was measured before neoadjuvant chemotherapy and esophagectomy. Multivariate analysis for infectious complications and prognosis was performed.

resultsThe study included 134 patients. The median weight loss during neoadjuvant chemotherapy was 2.83% (-2.07% to 6.29%). Postoperative infectious complications were observed in 37 patients who had a significantly higher weight loss during neoadjuvant chemotherapy (5.18% vs. 1.90%, P = 0.002). Multivariate analysis revealed that > 5% of weight loss during neoadjuvant chemotherapy was the only independent factor associated with postoperative infectious complications (odds ratio 2.69, 95% confidence interval 1.12-6.46, P = 0.027). Weight loss during neoadjuvant chemotherapy was significantly associated with worse recurrence-free survival in the univariate analysis (log-rank test, P = 0.002), but this association was marginal in the multivariate analysis (hazard ratio 1.73, 95% confidence interval 0.98-3.08, P = 0.058).

conclusionsSevere weight loss during neoadjuvant chemotherapy was an independent risk factor for postoperative infectious complications. Weight maintenance during neoadjuvant chemotherapy may reduce the incidence of postoperative infectious complications.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsCisplatinFluorouracilHumansNeoadjuvant TherapyPostoperative ComplicationsPrognosisWeight LossCisplatinFluorouracilEsophageal neoplasmsNeoadjuvant therapyPostoperative complicationsPrognosisWeight loss

Identifiers

PMID36494496
OpenAlexW4311026118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.